Results 101 to 110 of about 7,192,603 (344)
β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Molecular Oncology, EarlyView.Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero +8 more
wiley +1 more source
Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia [PDF]
, 2019 Paul C. McDonald +19 more
openalex +1 more source
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Nature reviews. Immunology, 2019 Karen V. Swanson, Meng Deng, J. Ting
semanticscholar +1 more source
Molecular Oncology, EarlyView.AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
MERVL/Zscan4 Network Activation Results in Transient Genome-wide DNA Demethylation of mESCs [PDF]
, 2016 Mélanie Eckersley-Maslin +12 more
openalex +1 more source
Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer [PDF]
, 2020 Shaoquan Zheng +8 more
openalex +1 more source
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease [PDF]
, 2022 Adrianne F. Pike +13 more
openalex +1 more source
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source